Sinus implant maker Intersect ENT files for an $80 million IPO

By
A A A

Intersect ENT, which sells drug-eluting implants that maintain relief from chronic sinusitis after surgery, filed on Monday with the SEC to raise up to $80 million in an initial public offering. The company lists Medtronic ( MDT ) among potential competitors, while the company also owns a 7% stake in Intersect ENT. The Menlo Park, CA-based company, which was founded in 2003 and booked $23 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol XENT. Intersect ENT initially filed confidentially on May 2, 2014. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: MDT

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

75%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com